Intracranial Hemorrhage as the Initial Presentation of Chronic-Phase Chronic Myeloid Leukemia in an Adolescent

To the Editor, Intracranial hemorrhage (ICH) is a rare initial manifestation of chronic-phase chronic myeloid leukemia (CML-CP), being far more often described in accelerated or blast phase, and few chronic-phase cases have been reported [1,2].We describe an adolescent in whom multifocal ICH was the presenting feature of CML-CP despite a normal platelet count and normal clotting times.A 17-year-old boy presented with a one-week history of headache, nausea, and vomiting.He was alert (Glasgow Coma Scale 15) without focal deficit, with hepatomegaly and marked splenomegaly (10 cm).The white blood cell (WBC) count was 479 × 10 9 /L, hemoglobin 6.9 g/dL, and platelet count 247 × 10 9 /L; prothrombin time, international normalized ratio, and activated partial thromboplastin time were normal, fibrinogen was 186 mg/dL, and D-dimer was mildly elevated (1.07 mg/L), without evidence of overt consumptive coagulopathy.Bone marrow examination confirmed CML-CP; conventional cytogenetics showed 46,XY,t(9;22)(q34;q11.2)[7]/46,XY[4],and real-time polymerase chain reaction detected the BCR::ABL1 p210 transcript at 24.3% on the International Scale.Cranial magnetic resonance imaging showed a 5 × 2.5 cm left frontobasal intraparenchymal hematoma with vasogenic edema, an 8-mm midline shift, and 4-mm caudal tonsillar displacement without clinical signs of herniation, plus a separate right frontoparietal hemorrhagic focus (Figure 1); the cerebral arteries and dural venous sinuses were patent, without ischemia on diffusion-weighted imaging.Because he remained neurologically stable, he was managed without leukapheresis or neurosurgery, with supportive care, hydroxyurea (20 mg/kg/day) from day 2, low-dose cytarabine (30 mg/m 2 every 12 hours) on days 4-9, and imatinib 400 mg daily after molecular confirmation.Leukapheresis was avoided because the hemorrhage and edema were judged to raise the risk of neurological deterioration.The WBC count fell below 20 × 10 9 /L by day 15, the hematoma resolved radiologically by month 2, and a deep molecular response (MR4.5) was achieved by month 12, without rebleeding.A normal platelet count, normal clotting times without consumptive coagulopathy, and patent cerebral arteries and venous sinuses make thrombocytopenia, coagulopathy, and venous sinus thrombosis unlikely; in extreme hyperleukocytosis, the multifocal hemorrhage is most consistent with leukostasis, which we consider the presumed, though unproven, mechanism.Extreme leukocytosis raises blood viscosity and leukocyte aggregates obstruct the microcirculation, causing hypoxia and endothelial injury, compounded by cytokine and protease release from activated leukocytes; the resulting microvascular disruption can culminate in hemorrhage.Because circulating cells in CML-CP are mainly maturing granulocytes, less rigid and adhesive than blasts, leukostasis and ICH are rarer than u n c o r r e c t e d p r o o f

Authors

Institutions

Publication Details

Journal
Turkish Journal of Hematology
Published
2026-11-16
DOI
https://doi.org/10.4274/tjh.galenos.2026.93384
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intracranial Hemorrhage as the Initial Presentation of Chronic-Phase Chronic Myeloid Leukemia in an Adolescent

Ali Fettah, Volkan Köse, Fatma Tuba YILDIRIM, Erkan Emrahoğlu et al.
Turkish Journal of Hematology
Chronic Myeloid Leukemia Treatments
article

Intracranial Hemorrhage as the Initial Presentation of Chronic-Phase Chronic Myeloid Leukemia in an Adolescent

Ali Fettah, Volkan Köse, Fatma Tuba YILDIRIM, Erkan Emrahoğlu, Zeynelabidin Öztürk
article en

Abstract

To the Editor, Intracranial hemorrhage (ICH) is a rare initial manifestation of chronic-phase chronic myeloid leukemia (CML-CP), being far more often described in accelerated or blast phase, and few chronic-phase cases have been reported [1,2].We describe an adolescent in whom multifocal ICH was the presenting feature of CML-CP despite a normal platelet count and normal clotting times.A 17-year-old boy presented with a one-week history of headache, nausea, and vomiting.He was alert (Glasgow Coma Scale 15) without focal deficit, with hepatomegaly and marked splenomegaly (10 cm).The white blood cell (WBC) count was 479 × 10 9 /L, hemoglobin 6.9 g/dL, and platelet count 247 × 10 9 /L; prothrombin time, international normalized ratio, and activated partial thromboplastin time were normal, fibrinogen was 186 mg/dL, and D-dimer was mildly elevated (1.07 mg/L), without evidence of overt consumptive coagulopathy.Bone marrow examination confirmed CML-CP; conventional cytogenetics showed 46,XY,t(9;22)(q34;q11.2)[7]/46,XY[4],and real-time polymerase chain reaction detected the BCR::ABL1 p210 transcript at 24.3% on the International Scale.Cranial magnetic resonance imaging showed a 5 × 2.5 cm left frontobasal intraparenchymal hematoma with vasogenic edema, an 8-mm midline shift, and 4-mm caudal tonsillar displacement without clinical signs of herniation, plus a separate right frontoparietal hemorrhagic focus (Figure 1); the cerebral arteries and dural venous sinuses were patent, without ischemia on diffusion-weighted imaging.Because he remained neurologically stable, he was managed without leukapheresis or neurosurgery, with supportive care, hydroxyurea (20 mg/kg/day) from day 2, low-dose cytarabine (30 mg/m 2 every 12 hours) on days 4-9, and imatinib 400 mg daily after molecular confirmation.Leukapheresis was avoided because the hemorrhage and edema were judged to raise the risk of neurological deterioration.The WBC count fell below 20 × 10 9 /L by day 15, the hematoma resolved radiologically by month 2, and a deep molecular response (MR4.5) was achieved by month 12, without rebleeding.A normal platelet count, normal clotting times without consumptive coagulopathy, and patent cerebral arteries and venous sinuses make thrombocytopenia, coagulopathy, and venous sinus thrombosis unlikely; in extreme hyperleukocytosis, the multifocal hemorrhage is most consistent with leukostasis, which we consider the presumed, though unproven, mechanism.Extreme leukocytosis raises blood viscosity and leukocyte aggregates obstruct the microcirculation, causing hypoxia and endothelial injury, compounded by cytokine and protease release from activated leukocytes; the resulting microvascular disruption can culminate in hemorrhage.Because circulating cells in CML-CP are mainly maturing granulocytes, less rigid and adhesive than blasts, leukostasis and ICH are rarer than u n c o r r e c t e d p r o o f

Turkish Journal of Hematology
Sağlık Bilimleri Üniversitesi (TR), Ankara Etlik City Hospital (TR)
Good health and well-being
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon